Treatment of Multiple Myeloma in a Heart Transplant Recipient
| Autor: | Indranee Rajapreyar, Keshava Rajagopal, Christina Paruthi, Phillip Weeks, Sriram Nathan, L. Maximilian Buja, Lola Xie, Biswajit Kar, Pranav Loyalka, Bartosz Jozwik, Robert E. Brown |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Transplantation
education.field_of_study business.industry Amyloidosis Population 030204 cardiovascular system & hematology 030230 surgery Plasma cell medicine.disease Malignancy Dyscrasia 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Immunology AL amyloidosis medicine business education Multiple myeloma Lenalidomide medicine.drug |
| Zdroj: | Progress in Transplantation. 27:65-68 |
| ISSN: | 2164-6708 1526-9248 |
| DOI: | 10.1177/1526924816679842 |
| Popis: | Malignancy following solid organ transplant remains a significant threat to the survival of cardiac transplant recipients. Plasma cell dyscrasias including multiple myeloma have been encountered in this population, and medication treatments traditionally used to treat these disorders demonstrate immunomodulatory effects that may have implications on the transplanted allograft. Lenalidomide is an immunomodulatory agent that has been used to treat plasma cell disorders, including light-chain amyloidosis (AL) and multiple myeloma, and represents such a class of medications in which the risks and benefits in the solid organ transplant population remain to be fully elucidated. This report highlights a clinical practice issue where the treatment of a patient’s multiple myeloma with lenalidomide may have potentiated an episode of severe acute cellular rejection and further demonstrates the need for future investigation of the optimal treatment of plasma cell disorders including AL amyloidosis and multiple myeloma following solid organ transplantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|